|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2005-1-11
|
|
pubmed:abstractText |
Rasburicase has been defined as a potent urolytic agent for management of malignancy-associated hyperuricemia. We reviewed the data of 26 children with malignancy at risk for TLS who received rasburicase for treatment or prophylaxis of acute hyperuricemia, producing a significant decrease in uric acid level in all the patients. Tolerance of treatment was excellent. Rasburicase is a safe, highly and rapidly effective agent in the treatment and prevention of malignancies-associated acute hyperuricemia.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1592-8721
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
90
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
141-2
|
|
pubmed:meshHeading |
pubmed-meshheading:15642687-Adolescent,
pubmed-meshheading:15642687-Antineoplastic Agents,
pubmed-meshheading:15642687-Child,
pubmed-meshheading:15642687-Child, Preschool,
pubmed-meshheading:15642687-Female,
pubmed-meshheading:15642687-Humans,
pubmed-meshheading:15642687-Hyperuricemia,
pubmed-meshheading:15642687-Infant,
pubmed-meshheading:15642687-Infant, Newborn,
pubmed-meshheading:15642687-Male,
pubmed-meshheading:15642687-Recombinant Proteins,
pubmed-meshheading:15642687-Tumor Lysis Syndrome,
pubmed-meshheading:15642687-Urate Oxidase
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Efficacy and safety of recombinant urate oxidase (rasburicase) for treatment and prophylaxis of hyperuricemia in children undergoing chemotherapy.
|
|
pubmed:publicationType |
Letter
|
